How do I subscribe to ongoing alerts?

Subscribe to /feed/company/groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives pipeline: 5 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Infliximab CT-P13	Infliximab CT-P13	marketed
Start adalimumab in monotherapy	Start adalimumab in monotherapy	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)	Immunology / Gastroenterology
Mirikizumab - SC	Mirikizumab - SC	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit	Immunology / Gastroenterology
Mirikizumab - IV	Mirikizumab - IV	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit	Immunology / Gastroenterology
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)	Immunology / Gastroenterology
Azathioprine OR Mesalazine	Azathioprine OR Mesalazine	phase 3	Immunosuppressant and anti-inflammatory combination	Purine metabolism (azathioprine); NF-κB pathway (mesalazine)	Gastroenterology / Immunology

Therapeutic area mix

Immunology / Gastroenterology · 4
Gastroenterology / Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Janssen Pharmaceutical K.K. · 2 shared drug classes
Alimentiv Inc. · 1 shared drug class
Children's Memorial Health Institute, Poland · 1 shared drug class
Caja Costarricense de Seguro Social · 1 shared drug class
Celltrion · 1 shared drug class
Centocor, Inc. · 1 shared drug class
Biocad · 1 shared drug class
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives:

Cite this brief

Drug Landscape (2026). Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives. Accessed 2026-05-18.